Xention looks to ion technology to jump start safer treatments
This article was originally published in Scrip
Executive Summary
While the patent cliff looms ever closer for big pharma, some smaller companies are not looking to untreated diseases to develop the new blockbuster but to conditions that are already catered for, albeit badly. The CEO of Cambridge, UK-based Xention, Dr Tim Brears, told Scrip how his company is using ion channel technologies to develop targeted products with far better safety profiles than the drugs that have been used to treat certain ailments for decades.